Augmentation of Oncolytic Viral Efficacy through Immunological Targeting Tumor Endothelial Cells
AssigneeBatu Biologics, Inc.
InventorsSamuel C. Wagner, Thomas E. Ichim
Life of this patent
Estimating the term…
Loading patent…
AssigneeBatu Biologics, Inc.
InventorsSamuel C. Wagner, Thomas E. Ichim
Estimating the term…
Disclosed are means of treatment of cancer by enhancing efficacy of oncolytic virus ability to eradicate tumors through the destruction/inactivation of cancer endothelial cells through immunological means. In one embodiment of the invention, administration of placental endothelial cells generated antitumor endothelial immune responses are used to sensitize tumors to oncolytic viral entry. In another embodiment, oncolytic viruses are utilized to enhance generation of cancer endothelial specific responses by causing localized inflammation in the tumor endothelium, which enhances efficacy of the tumor endothelial targeting vaccine. In another embodiment, the invention teaches the use of replication deficient oncolytic viruses to deliver proteins to tumor cells in an immunogenic manner such that proteins encoded by the oncolytic viruses induce immunity to tumor endothelial cell antigens.
A method of inducing antitumor immune responses comprising:
Dependencies are inferred from the claim text.